Findings build on the LATITUDE study, which demonstrated that CAB + RPV LA was superior to daily oral therapy in maintaining viral suppression among people with HIV who had achieved viral suppression on oral ART but had a history of adherence challenges. CROWN addresses a remaining evidence gap by evaluating direct initiation of the regimen in people who still had detectable virus at study entry and had no evidence of resistance to INSTIs (integrase inhibitors) or NNRTIs (non-nucleoside reverse transcriptase inhibitors). Use of CAB + RPV LA in people with detectable viremia is investigational and has not been approved by regulatory authorities.
Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said:
People living with HIV who experience challenges achieving or maintaining viral suppression with daily oral therapy continue to face significant barriers to optimising care. The CROWN study was designed to address this important evidence gap. These findings add to the growing body of data around long-acting treatment with cabotegravir plus rilpivirine, and provide important insights into the potential role of this approach for treatment-experienced people living with HIV.
CROWN is an international, randomised, open-label study designed to evaluate whether people living with HIV-1 who have detectable virus despite a history of daily oral ART can directly initiate CAB + RPV LA, administered six times a year, and achieve viral suppression. The study enrolled approximately 326 participants, including adults and adolescents, across eight countries at 85 study sites.
CAB + RPV LA is currently approved in the US and other markets under the brand name Cabenuva and Vocabria + Rekambys in the EU and Japan for the treatment of HIV-1 infection in adults and adolescents who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Full results are planned for presentation at an upcoming scientific meeting.